Integrative Analysis of Human Glioblastoma Multiforme

NCT03005132 · tracked via the Priya Life Science China tracker

Sponsor

Shanghai 10th People's Hospital

Phase

Observational

Started

2016-01

Last updated

2016-12-29

Condition(s) studied

GBM

Investigational drug(s) / intervention(s)

Normal brain tissue

Normal brain tissue: The investigators will extract total protein, DNA and RNA from the samples.

Study summary

Integrative analysis of GBM

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: * Age ≤ 75 years with histologically proven GBM * No severe major organ dysfunction * World Health Organization (WHO) performance status of 0 or 1 * No prior cancer chemotherapy Exclusion Criteria: * Age ≥ 76 * Severe major organ dysfunction * WHO performance status of \>1 * Prior cancer chemotherapy

Primary outcome measure(s)

5 years overall survival — 5 years

Trial sites (1)

Facility	City	Region	Status
Shanghai Tenth People's Hospital	Shanghai	Shanghai Municipality	Recruiting

More Shanghai 10th People's Hospital trials in China

Study of the Closed-loop Treatment Concept of Atrial Fibrillation in the Atrial Fibrillation Population Recruiting

D615L vs Zeiss 839MP: Visual Quality Active, not recruiting

A Multicenter Clinical Study on Protein Absorption Efficiency in Patients With Pancreatic Exocrine Insufficiency in the ICU Starting soon

Efficacy and Safety of Coenzyme I for Injection on Vascular Aging. Starting soon

Multidisciplinary Diagnosis and Treatment of Polycystic Ovary Syndrome Recruiting

Other trials for the same condition

Clinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma Starting soon

Evaluate the Efficacy and Safety of ADCV01 As an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients Recruiting

Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03005132 on ClinicalTrials.gov ↗ ← All trials in China